What 8 Analyst Ratings Have To Say About Genmab
Portfolio Pulse from Benzinga Insights
In the last three months, 8 analysts have evaluated Genmab (NASDAQ:GMAB), with all ratings being bullish. Analysts have set 12-month price targets for Genmab, with an average target of $50.0, a high of $53.00, and a low of $47.00. Recent evaluations show a slight upward trend in price targets. Genmab's financials reveal strong revenue growth, net margin, ROE, ROA, and low debt-to-equity ratio.
July 15, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Genmab has received 8 bullish ratings from analysts in the last three months, with an average 12-month price target of $50.0. The company's strong financial performance, including high revenue growth and profitability, supports this positive outlook.
All 8 analysts have rated Genmab bullish, indicating strong confidence in the company's future performance. The upward trend in price targets and robust financial metrics such as high revenue growth, net margin, ROE, and ROA further support a positive short-term impact on the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100